腟がん(Vaginal Cancer):治療薬開発パイプライン動向(2016年下半期版)

Global Markets Directが発行した調査報告書(DATA70209358)
◆英語タイトル:Vaginal Cancer - Pipeline Review, H2 2016
◆商品コード:DATA70209358
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月30日
◆ページ数:68
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における腟がん(Vaginal Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・腟がん(Vaginal Cancer)の概要
・腟がん(Vaginal Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・腟がん(Vaginal Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・腟がん(Vaginal Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・腟がん(Vaginal Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Vaginal Cancer – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer – Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.

Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively.Vaginal Cancer.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vaginal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Vaginal Cancer – Overview 7
Vaginal Cancer – Therapeutics under Development by Companies 8
Vaginal Cancer – Pipeline Products Glance 9
Clinical Stage Products 9
Vaginal Cancer – Products under Development by Companies 10
Vaginal Cancer – Companies Involved in Therapeutics Development 11
ISA Pharmaceuticals BV 11
Nanotherapeutics Inc 12
Ono Pharmaceutical Co Ltd 13
Oryx GmbH & Co KG 14
PDS Biotechnology Corp 15
Taiwan Liposome Company Ltd 16
Vaginal Cancer – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ISA-101 – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
nivolumab – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
NTO-1151 – Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
PDS-0101 – Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
TLC-388 – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Vicoryx – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Vaginal Cancer – Dormant Projects 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Vaginal Cancer, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Products under Development by Companies, H2 2016 10
Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016 11
Vaginal Cancer - Pipeline by Nanotherapeutics Inc, H2 2016 12
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 13
Vaginal Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016 14
Vaginal Cancer - Pipeline by PDS Biotechnology Corp, H2 2016 15
Vaginal Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Vaginal Cancer - Dormant Projects, H2 2016 70

List of Figures
Number of Products under Development for Vaginal Cancer, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

【レポートのキーワード】

腟がん(Vaginal Cancer)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 腟がん(Vaginal Cancer):治療薬開発パイプライン動向(2016年下半期版)(Vaginal Cancer - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆